BTAI vs BYSI

BioXcel Therapeutics, Inc. vs BeyondSpring, Inc. — Valuation Comparison 2026

BTAI

Pharmaceutical Preparations
BioXcel Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$1.17
Last close
Models
4/13
Active
VS

BYSI

Pharmaceutical Preparations
BeyondSpring, Inc.
Quality
3.5
out of 10
Value Trap
24
SAFE
Price
$1.68
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType BTAI Fair ValueBTAI Upside BYSI Fair ValueBYSI Upside
Bayesian DCF Intrinsic $3.63 +152.2%
Earnings Power Value Intrinsic $0.75 -49.6%
EROIC Spread Intrinsic $1.49 +24.3% $0.31 -79.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $3.95 +237.3% $2.29 +36.3%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BTAI vs BYSI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BTAI vs BYSI — Which Stock Is More Undervalued?

BTAI scores higher with a 4.4/10 quality rating vs BYSI's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BioXcel Therapeutics, Inc. (BTAI) and BeyondSpring, Inc. (BYSI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BTAI currently trades at $1.17 with a QOC of 4.4/10, while BYSI trades at $1.68 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).